GLP1R and myocardial infarction: Only GLP1-RA reduced the relative risk of myocardial infarction by 9% (HR, 0.91; 95% CI, 0.85–0.98; P = 0.008; P for heterogeneity, 0.13), whereas finerenone had no effect on lowering the relative risk of myocardial infarction (HR, 0.90; 95% CI, 0.74–1.11; P = 0.34; P for heterogeneity, 0.32; Figure S3 shows this in more detail [see Additional file 1]).